Noelia Nebot1, Hendrik-Tobias Arkenau2, Jeffrey R Infante3, Jason C Chandler4, Andrew Weickhardt5, Jason D Lickliter6, John Sarantopoulos7, Michael S Gordon8, Gabriel Mak9, Annie St-Pierre10, Lihua Tang11, Bijoyesh Mookerjee1, Stanley W Carson11, Siobhan Hayes12, Kenneth F Grossmann13. 1. Novartis Pharmaceuticals Corporation, East Hanover, NJ, 07936, USA. 2. Sarah Cannon Research Institute and University College London, London, W1G 6AD, UK. 3. Sarah Cannon Research Institute, Nashville, TN, 37203, USA. 4. West Cancer Center, Memphis, TN, USA. 5. Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Australia. 6. Nucleus Network, Melbourne, VIC, 3004, Australia. 7. Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA. 8. Pinnacle Oncology Hematology/HonorHealth Research Institute, Scottsdale, AZ, 85258, USA. 9. Sarah Cannon Research Institute UK, London, W1G 6AD, UK. 10. Novartis Pharma AG, Basel, Switzerland. 11. Novartis Pharmaceuticals Corporation, Morrisville, NC, USA. 12. ICON, Marlow, UK. 13. Huntsman Cancer Institute, Salt Lake City, UT, 84112, USA.
Abstract
AIMS: The effect of repeat oral supratherapeutic dosing of the BRAF inhibitor dabrafenib on QTc interval was assessed in patients with BRAF V600-mutant tumours. METHODS: Part 1 of this phase 1, multicentre, 2-part study (BRF113773/NCT01738451) assessed safety/tolerability of dabrafenib225 or 300 mg twice daily (BID) to inform part 2 dosing. Patients in part 2 received dabrafenib-matched placebo on day -1, single-dose dabrafenib 300 mg on day 1, 300 mg BID on days 2 to 7, and 300 mg on day 8 (morning), followed by 24-h Holter electrocardiographic monitoring and pharmacokinetics sample collection each dose day. Pharmacokinetics/pharmacodynamics analysis assessed combined dabrafenib and metabolite effects on QTc interval. RESULTS: Part 1 (n = 12) determined supratherapeutic dosing, 300 mg BID, for part 2. Thirty-one patients completed part 2. Mean maximum ΔΔQTcF occurred on day 8, 10 h postdose (2.86 msec; 90% CI, -1.36 to 7.07). Categorical analysis showed no placebo and dabrafenib outliers (increase >60 msec; QTcF >500 msec). Day 1 dabrafenib 300 mg Cmax and AUC(0-∞) were ≈ 2-fold higher than with single-dose 150 mg. Day 8 AUC(0-τ) with 300 mg BID was ≈ 2.7-fold higher than with 150 mg BID. Dabrafenib metabolites showed similar trends. Pharmacokinetics/pharmacodynamics modelling/simulation showed that median QTc increase was <5 msec (upper 90% CI, <10 msec). No unexpected toxicities occurred with supratherapeutic dosing. CONCLUSION:Repeat oral supratherapeutic dabrafenib 300 mg BID dosing had no clinically relevant effect on QTc interval, with no new safety signals seen.
RCT Entities:
AIMS: The effect of repeat oral supratherapeutic dosing of the BRAF inhibitor dabrafenib on QTc interval was assessed in patients with BRAF V600-mutant tumours. METHODS: Part 1 of this phase 1, multicentre, 2-part study (BRF113773/NCT01738451) assessed safety/tolerability of dabrafenib 225 or 300 mg twice daily (BID) to inform part 2 dosing. Patients in part 2 received dabrafenib-matched placebo on day -1, single-dose dabrafenib 300 mg on day 1, 300 mg BID on days 2 to 7, and 300 mg on day 8 (morning), followed by 24-h Holter electrocardiographic monitoring and pharmacokinetics sample collection each dose day. Pharmacokinetics/pharmacodynamics analysis assessed combined dabrafenib and metabolite effects on QTc interval. RESULTS: Part 1 (n = 12) determined supratherapeutic dosing, 300 mg BID, for part 2. Thirty-one patients completed part 2. Mean maximum ΔΔQTcF occurred on day 8, 10 h postdose (2.86 msec; 90% CI, -1.36 to 7.07). Categorical analysis showed no placebo and dabrafenib outliers (increase >60 msec; QTcF >500 msec). Day 1 dabrafenib 300 mg Cmax and AUC(0-∞) were ≈ 2-fold higher than with single-dose 150 mg. Day 8 AUC(0-τ) with 300 mg BID was ≈ 2.7-fold higher than with 150 mg BID. Dabrafenib metabolites showed similar trends. Pharmacokinetics/pharmacodynamics modelling/simulation showed that median QTc increase was <5 msec (upper 90% CI, <10 msec). No unexpected toxicities occurred with supratherapeutic dosing. CONCLUSION: Repeat oral supratherapeutic dabrafenib 300 mg BID dosing had no clinically relevant effect on QTc interval, with no new safety signals seen.
Authors: Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean-Jacques Grob; Vanna Chiarion-Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Suzanne Swann; Jeffrey J Legos; Fan Jin; Bijoyesh Mookerjee; Keith Flaherty Journal: Lancet Date: 2015-05-31 Impact factor: 79.321
Authors: Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2017-12 Impact factor: 8.739
Authors: Daniele Ouellet; Kenneth F Grossmann; Giselle Limentani; Noelia Nebot; Kevin Lan; Lara Knowles; Michael S Gordon; Sunil Sharma; Jeffrey R Infante; Patricia M Lorusso; Girish Pande; Elizabeth C Krachey; Samuel C Blackman; Stanley W Carson Journal: J Pharm Sci Date: 2013-04-22 Impact factor: 3.534
Authors: Noelia Nebot; Hendrik-Tobias Arkenau; Jeffrey R Infante; Jason C Chandler; Andrew Weickhardt; Jason D Lickliter; John Sarantopoulos; Michael S Gordon; Gabriel Mak; Annie St-Pierre; Lihua Tang; Bijoyesh Mookerjee; Stanley W Carson; Siobhan Hayes; Kenneth F Grossmann Journal: Br J Clin Pharmacol Date: 2018-01-23 Impact factor: 4.335
Authors: Georgina V Long; Jeffrey S Weber; Jeffrey R Infante; Kevin B Kim; Adil Daud; Rene Gonzalez; Jeffrey A Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Richard F Kefford; Donald Lawrence; Ragini Kudchadkar; Howard A Burris; Gerald S Falchook; Alain Algazi; Karl Lewis; Igor Puzanov; Nageatte Ibrahim; Peng Sun; Elizabeth Cunningham; Amy S Kline; Heather Del Buono; Diane Opatt McDowell; Kiran Patel; Keith T Flaherty Journal: J Clin Oncol Date: 2016-01-25 Impact factor: 44.544
Authors: G V Long; K T Flaherty; D Stroyakovskiy; H Gogas; E Levchenko; F de Braud; J Larkin; C Garbe; T Jouary; A Hauschild; V Chiarion-Sileni; C Lebbe; M Mandalà; M Millward; A Arance; I Bondarenko; J B A G Haanen; J Hansson; J Utikal; V Ferraresi; P Mohr; V Probachai; D Schadendorf; P Nathan; C Robert; A Ribas; M A Davies; S R Lane; J J Legos; B Mookerjee; J-J Grob Journal: Ann Oncol Date: 2017-07-01 Impact factor: 32.976
Authors: Tyler C Beck; Kendra Springs; Jordan E Morningstar; Catherine Mills; Andrew Stoddard; Lilong Guo; Kelsey Moore; Cortney Gensemer; Rachel Biggs; Taylor Petrucci; Jennie Kwon; Kristina Stayer; Natalie Koren; Jaclyn Dunne; Diana Fulmer; Ayesha Vohra; Le Mai; Sarah Dooley; Julianna Weninger; Yuri Peterson; Patrick Woster; Thomas A Dix; Russell A Norris Journal: Molecules Date: 2022-06-08 Impact factor: 4.927
Authors: Noelia Nebot; Hendrik-Tobias Arkenau; Jeffrey R Infante; Jason C Chandler; Andrew Weickhardt; Jason D Lickliter; John Sarantopoulos; Michael S Gordon; Gabriel Mak; Annie St-Pierre; Lihua Tang; Bijoyesh Mookerjee; Stanley W Carson; Siobhan Hayes; Kenneth F Grossmann Journal: Br J Clin Pharmacol Date: 2018-01-23 Impact factor: 4.335
Authors: Lucie Heinzerling; Thomas K Eigentler; Michael Fluck; Jessica C Hassel; Daniela Heller-Schenck; Jan Leipe; Matthias Pauschinger; Arndt Vogel; Lisa Zimmer; Ralf Gutzmer Journal: ESMO Open Date: 2019-05-23
Authors: Daniel N Meijles; Joshua J Cull; Susanna T E Cooper; Thomais Markou; Michelle A Hardyman; Stephen J Fuller; Hajed O Alharbi; Zoe H R Haines; Viridiana Alcantara-Alonso; Peter E Glennon; Mary N Sheppard; Peter H Sugden; Angela Clerk Journal: Clin Sci (Lond) Date: 2021-07-30 Impact factor: 6.124